A Recurrence Risk Score Model Evaluating Effects of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologically Negative Lymph Nodes after Neoadjuvant Chemotherapy: A Multicenter, Retrospective Study
Dan-Qiong Wang,Zhou Huang,Hong-Fen Wu,Dong-Xing Shen,Hao Jing,Hui Fang,Li Zhu,Xiao-Bo Huang,Liangfang Shen,Mei Shi,Jiayi Chen,Min Liu,Jing Cheng,Ye-Xiong Li,Jian Tie,Yu Tang,Shu-Lian Wang
DOI: https://doi.org/10.2139/ssrn.4826898
2024-01-01
Abstract:Purpose: To evaluate the effects of postmastectomy radiotherapy (PMRT) in breast cancer patients with pathologically negative lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC).Patients and methods: This multicenter retrospective study assessed the data of 766 breast cancer patients with ypN0 and established a recurrent risk score model based on a disease-free survival (DFS) rate–based multivariate Cox model. Moreover, the locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) rates in PMRT and non-PMRT patients were calculated using the Kaplan–Meier method.Results: All patients received a median of four NAC cycles, followed by mastectomy and axillary lymph node dissection; moreover, 353 (46.1%) patients underwent PMRT. Over a median follow-up duration of 74 months, the 5-year LRC, DFS, and OS rates for all patients were 96.5%, 89.1%, and 95.3%, respectively. The differences in the LRC, DFS, and OS rates between PMRT and non-PMRT patients were nonsignificant in the univariate and multivariate analyses. By using our recurrent risk score model based on five factors (i.e., age, clinical N stage, NAC cycle number, lymphovascular invasion, and pathological tumor stage after NAC), we stratified the patients into low-, intermediate- and high-risk groups; their 5-year rates of LRC (98.6%, 95.5%, and 89.8%, respectively), DFS (94.4%, 87.4%, and 71.5%, respectively), and OS (97.6%, 93.2%, and 90.0%, respectively) were significantly different (all P < 0.001). PMRT did not improve survival outcomes in any of the subgroupsConclusion: Our recurrence risk score model effectively distinguished ypN0 patients with different recurrent risk stratifications. However, no subgroup was identified to benefit from PMRT.